Journal Home > Volume 6 , Issue 1

menu
Full text
Outline
About this article

Commemorating a modest, rigorous, and great scientist for Neurorestoratology

Show Author's information Lin Chen1Hari Sharma2
 Department of Neurosurgery, Tsinghua University Yuquan Hospital, Beijing, China
 International Experimnetal Central Nervous System Injury & Repair (IECNSIR), Dept. of Surgical Sciences, University Hospital, Uppsala University, Uppsala, Sweden

References(32)

[1]
Skaper SD. Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: A strategy for neuroprotection. Ann N Y Acad Sci. 2003, 993: 217-228.
[2]
Facci L, Stevens DA, Skaper SD. Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport. 2003, 14(11): 1467-1470.
[3]
Skaper SD, Facci L, Williams G, et al. A dimeric version of the short N-cadherin binding motif HAVDI promotes neuronal cell survival by activating an N-cadherin/fibroblast growth factor receptor signalling cascade. Mol Cell Neurosci. 2004, 26(1): 17-23.
[4]
Irving EA, Vinson M, Rosin C, et al. Identification of neuroprotective properties of anti-MAG antibody: a novel approach for the treatment of stroke? J Cereb Blood Flow Metab. 2005, 25(1): 98-107.
[5]
Skaper SD. Neuronal growth-promoting and inhibitory cues in neuroprotection and neuroregeneration. Ann N Y Acad Sci. 2005, 1053: 376-385.
[6]
Skaper SD, Facci L, Culbert AA, et al. P2X(7) receptors on microglial cells mediate injury to cortical neurons in vitro. Glia. 2006, 54(3): 234-242.
[7]
Marco S, Skaper SD. Amyloid beta-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett. 2006, 401(3): 219-224.
[8]
Skaper SD. The brain as a target for inflammatory processes and neuroprotective strategies. Ann N Y Acad Sci. 2007, 1122: 23-34.
[9]
Skaper SD. Signalling pathways with small molecule mimetics and modulators to achieve neuroprotection and regeneration. CNS Neurol Disord Drug Targets 2008, 7(1): 45.
[10]
Skaper SD, Evans NA, Evans NA, et al. Oligodendrocytes are a novel source of amyloid peptide generation. Neurochem Res. 2009, 34(12): 2243-2250.
[11]
Skaper SD, Debetto P, Giusti P. The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J. 2010, 24(2): 337-345
[12]
Skaper SD. Ion channels on microglia: therapeutic targets for neuroprotection. CNS Neurol Disord Drug Targets 2011, 10(1): 44-56.
[13]
Skaper SD. Putting a finger on neurotrophic protein therapy in Parkinson’s disease. Commentary. CNS Neurol Disord Drug Targets 2011, 10(3): 295.
[14]
Facci L, Skaper SD. Amyloid β-peptide neurotoxicity assay using cultured rat cortical neurons. Methods Mol Biol. 2012, 846: 57-65.
[15]
Skaper SD. Culture of rat retina pigmented epithelial cells. Methods Mol Biol. 2012, 846: 159-166.
[16]
Skaper SD. Isolation and culture of rat cone photoreceptor cells. Methods Mol Biol. 2012, 846: 147-158.
[17]
Skaper SD. Culture of purified glial cell populations from optic nerve. Methods Mol Biol. 2012, 846: 131-145.
[18]
Skaper SD. Rodent retinal ganglion cell cultures. Methods Mol Biol. 2012, 846: 117-129.
[19]
Skaper SD, Mercanti G, Facci L. Culture and characterization of rat mesencephalic dopaminergic neurons. Methods Mol Biol. 2012, 846: 91-101.
[20]
di Marzo V, Skaper SD. Palmitoylethanolamide: Biochemistry, pharmacology and therapeutic use of a pleiotropic anti- inflammatory lipid mediator. CNS Neurol Disord Drug Targets 2013, 12(1): 4-6.
[21]
Skaper SD. Conference report: 8th annual meeting of the society for the study of neuroprotection and neuroplasticity. CNS Neurol Disord Drug Targets 2012, 11(4): 333-334.
[22]
Skaper SD, Giusti P, Facci L. Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J. 2012, 26(8): 3103-3117.
[23]
Skaper SD, Giusti P. Transgenic mouse models of Parkinson’s disease and Huntington’s disease. CNS Neurol Disord Drug Targets 2010, 9(4): 455-470.
[24]
Sharma HS, Skaper SD, Sharma A. Conference Report: 10th Clinical Trials on Alzheimer’s Disease (CTAD), Boston MA, USA, November 1–4, 2017. CNS Neurol Disord Drug Targets 2018, 16(10): 1134-1137.
[25]
Skaper SD. Amyotrophic lateral sclerosis: targeting the body’s energy engine. CNS Neurol Disord Drug Targets 2013, 12(2): 294.
[26]
Skaper SD. Mast cell-glia dialogue in chronic pain and neuropathic pain: Blood-brain barrier implications. CNS Neurol Disord Drug Targets 2016, 15(9): 1072-1078.
[27]
Graziottin A, Skaper SD, Fusco M. Mast cells in chronic inflammation, pelvic pain and depression in women. Gynecol Endocrinol. 2014, 30(7): 472-477.
[28]
Skaper SD, Di Marzo V. Endocannabinoids in nervous system health and disease: the big picture in a nutshell. Philos Trans R Soc Lond B Biol Sci. 2012, 367(1607): 3193-3200.
[29]
Skaper SD. Wnt-signalling: A new direction for alzheimer disease? CNS Neurol Disord Drug Targets 2014, 13(4): 556.
[30]
Chen L, Guo J, Sharma A, et al. Summary report of the International Association of Neurorestoratology VII Conference: Regulations, ethics, science, and the need of patients care in neurorestoratology. CNS Neurol Disord Drug Targets 2014, 13(6): 921-925.
[31]
Skaper SD, Facci L, Giusti P. Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: A review. CNS Neurol Disord Drug Targets 2014, 13(10): 1654-1666.
[32]
Skaper SD. Nerve growth factor: A neuroimmune crosstalk mediator for all seasons. Immunology. 2017, 151(1): 1-15.
Publication history
Rights and permissions

Publication history

Published: 26 June 2018
Issue date: December 2018

Rights and permissions

Return